NYSE:AIM AIM ImmunoTech (AIM) Stock Price, News & Analysis $0.36 +0.01 (+2.82%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.35▼$0.3750-Day Range$0.35▼$0.4552-Week Range$0.31▼$0.72Volume160,471 shsAverage Volume234,326 shsMarket Capitalization$18.79 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesSEC FilingsTrends Get AIM ImmunoTech alerts: Email Address Ad Awesomely, LLCAutomatic Income (from home)Everyone’s talking about this new income hack that could generate triple digit returns on your money. But here’s the best part…Watch this short video About AIM ImmunoTech Stock (NYSE:AIM)AIM ImmunoTech Inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders in the United States. The company's lead product candidate is Ampligen, a drug of macromolecular ribonucleic acid molecules for the treatment of chronic fatigue syndrome (CFS). It is also developing Ampligen for the treatment of pancreatic, renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, and prostate cancers, as well as for myalgic encephalomyelitis, Hepatitis B, HIV, COVID-19, and post-COVID conditions. In addition, the company provides Alferon N Injection, an injectable formulation of natural alpha interferon to treat human papilloma viruses, and genital warts, a sexually transmitted disease. AIM ImmunoTech Inc. has agreements with Amarex Clinical Research LLC; University of Cagliari Dipartimento di Scienze della Vita e dell'Ambiente; Jubilant HollisterStier; Sterling Pharma Solutions; Erasmus University Medical Center Rotterdam; Azenova, LLC; and Alcami Corporation. The company was formerly known as Hemispherx Biopharma, Inc. and changed its name to AIM ImmunoTech Inc. in August 2019. AIM ImmunoTech Inc. was incorporated in 1966 and is headquartered in Ocala, Florida.Read More AIM Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AIM Stock News HeadlinesJuly 25 at 12:00 PM | finance.yahoo.comAIM Announces New Positive Data on Ampligen’s Anti-Tumor Potential When Used as Part of a Combination TherapyJuly 24 at 8:50 AM | globenewswire.comAIM Announces New Positive Data on Ampligen's Anti-Tumor Potential When Used as Part of a Combination TherapyJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.July 3, 2024 | globenewswire.comAIM ImmunoTech Announces Release of the Next CEO Corner SegmentJune 10, 2024 | globenewswire.comAIM ImmunoTech to Participate in the Virtual Investor Pitch ConferenceJune 3, 2024 | globenewswire.comAIM ImmunoTech to Participate in the Virtual Investor Lunch Break SeriesMay 31, 2024 | globenewswire.comAIM ImmunoTech Announces Pricing of $2.0 Million Registered Direct OfferingMay 20, 2024 | globenewswire.comAIM ImmunoTech to Participate in Two Upcoming Investor ConferencesJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 17, 2024 | markets.businessinsider.comBuy Rating Affirmed: AIM ImmunoTech’s Ampligen Shows Promising Oncology Pipeline ProgressMay 17, 2024 | finance.yahoo.comQ1 2024 AIM ImmunoTech Inc Earnings CallMay 17, 2024 | msn.comAIM ImmunoTech Inc. (AMEX:AIM) Q1 2024 Earnings Call TranscriptMay 16, 2024 | finanznachrichten.deAIM ImmunoTech Inc.: AIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 16, 2024 | investorplace.comAIM Stock Earnings: AIM ImmunoTech Misses EPS for Q1 2024May 16, 2024 | globenewswire.comAIM ImmunoTech Reports First Quarter 2024 Financial Results and Provides Corporate UpdateMay 15, 2024 | msn.comAIM ImmunoTech Q1 2024 Earnings PreviewMay 9, 2024 | globenewswire.comAIM ImmunoTech to Discuss First Quarter 2024 Financial Results on May 16, 2024, and Host Conference Call and WebcastMay 6, 2024 | finanznachrichten.deAIM ImmunoTech Inc.: AIM ImmunoTech Completes cGMP Manufacturing of Clinical Vials of Ampligen®See More Headlines Receive AIM Stock News and Ratings via Email Sign-up to receive the latest news and ratings for AIM ImmunoTech and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/16/2024Today7/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNYSE SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNYSE:AIM CUSIPN/A CIK946644 Webaimimmuno.com Phone(352) 448-7797Fax215-988-1739Employees26Year Founded1990Profitability EPS (Most Recent Fiscal Year)($0.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-28,960,000.00 Net Margins-16,123.32% Pretax Margin-16,123.32% Return on Equity-191.38% Return on Assets-128.26% Debt Debt-to-Equity Ratio0.23 Current Ratio1.14 Quick Ratio1.14 Sales & Book Value Annual Sales$200,000.00 Price / Sales92.70 Cash FlowN/A Price / Cash FlowN/A Book Value$0.20 per share Price / Book1.80Miscellaneous Outstanding Shares51,500,000Free Float51,486,000Market Cap$18.54 million OptionableNot Optionable Beta-0.35 Social Links 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesMr. Thomas K. Equels Esq. (Age 71)J.D., M.S., Executive Vice Chairman, CEO & President Comp: $953.19kMr. Robert Dickey IV (Age 68)M.B.A., Chief Financial Officer Comp: $64.48kMr. Peter W. Rodino III (Age 73)Esq., J.D., COO, Executive Director of Governmental Relations, General Counsel & Secretary Comp: $484.94kAnn Marie E. CoverlyDirector of Administration & Human Resources and Deputy Investor Relations CoordinatorDr. Carol A. Smith (Age 73)Chief Manufacturing Officer & Deputy Chief Scientific Officer Comp: $170.77kDr. Christopher McAleer Ph.D.Scientific OfficerDr. Ralph Christopher Cavalli Ph.D. (Age 66)Vice President of QC & Manufacturing Comp: $234.79kMore ExecutivesKey CompetitorsCEL-SCINYSE:CVMGritstone bioNASDAQ:GRTSCognition TherapeuticsNASDAQ:CGTXPrecision BioSciencesNASDAQ:DTILJATT AcquisitionNYSE:JATTView All CompetitorsInsidersThomas K EquelsBought 61,729 shares on 5/6/2024Total: $25,308.89 ($0.41/share)Peter W Rodino IIIBought 30,865 shares on 5/6/2024Total: $12,654.65 ($0.41/share)Nancy BryanBought 38,462 shares on 3/21/2024Total: $15,000.18 ($0.39/share)Thomas K EquelsBought 75,758 shares on 3/15/2024Total: $25,000.14 ($0.33/share)Stewart AppelrouthBought 90,910 shares on 3/15/2024Total: $30,000.30 ($0.33/share)View All Insider Transactions AIM Stock Analysis - Frequently Asked Questions How have AIM shares performed this year? AIM ImmunoTech's stock was trading at $0.4399 at the beginning of the year. Since then, AIM shares have decreased by 17.0% and is now trading at $0.3649. View the best growth stocks for 2024 here. How were AIM ImmunoTech's earnings last quarter? AIM ImmunoTech Inc. (NYSE:AIM) announced its quarterly earnings data on Thursday, May, 16th. The company reported ($0.12) earnings per share (EPS) for the quarter. The business had revenue of $0.04 million for the quarter. AIM ImmunoTech had a negative trailing twelve-month return on equity of 191.38% and a negative net margin of 16,123.32%. How do I buy shares of AIM ImmunoTech? Shares of AIM stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of AIM ImmunoTech own? Based on aggregate information from My MarketBeat watchlists, some other companies that AIM ImmunoTech investors own include Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), iBio (IBIO), Vaxart (VXRT), Tonix Pharmaceuticals (TNXP), VBI Vaccines (VBIV) and T2 Biosystems (TTOO). This page (NYSE:AIM) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredMust-See: Elon’s New Invention is Absolutely InsaneCould Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredElon to Transform U.S. Economy? A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” ...Porter & Company | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding AIM ImmunoTech Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share AIM ImmunoTech With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.